Recce has successfully dosed half of target patients with RECCE 327 in its Phase 2 trial for Acute Bacterial Skin Infections. Don't miss out on the headlines from Stockhead. Followed categories will ...
Recce has successfully dosed half of target patients with RECCE 327 in its Phase 2 trial for Acute Bacterial Skin Infections. Special Report: Recce Pharmaceuticals has announced the successful dosing ...
Recce has successfully dosed half of target patients with RECCE 327 in its Phase 2 trial for Acute Bacterial Skin Infections. Clinical study review board remains on track to review the data in ...
Clinical study review board remains on track to review the data in mid-October with interim results to follow Special Report: Recce Pharmaceuticals has announced the successful dosing of half of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback